Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Moleculin Biotech Stock Down 0.4 %

Shares of MBRX stock opened at $2.46 on Wednesday. The firm’s 50-day moving average is $2.82 and its two-hundred day moving average is $4.36. Moleculin Biotech has a 12 month low of $2.12 and a 12 month high of $15.75.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.13). As a group, equities analysts predict that Moleculin Biotech will post -8.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned 9.60% of Moleculin Biotech as of its most recent filing with the SEC. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About Moleculin Biotech

(Get Free Report)

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.

Featured Stories